Peptides

CJC-1295 and ipamorelin: what the evidence actually shows

By the US Health Digest editorial team · Published August 8, 2026 · Every claim linked to its primary source

CJC-1295 and ipamorelin do raise growth hormone in small studies of healthy volunteers — and no clinical trial has ever tested either one, alone or combined, for anti-aging, muscle gain, fat loss, sleep, or recovery, the uses clinics sell them for. CJC-1295's human record is a pair of placebo-controlled safety studies from 2005–2006; ipamorelin's one randomized trial in patients — post-surgical bowel recovery, not wellness — found "no significant differences between ipamorelin and placebo." Neither is an approved drug; ipamorelin acetate sits on FDA's list of compounding substances that "may present significant safety risks." We publish no dosing for either.

What they are, and what they are sold for

The two molecules pull different levers of the same axis. CJC-1295 is a long-acting analog of growth-hormone-releasing hormone (GHRH), engineered to bind to albumin so a signal normally lasting minutes persists for days — its measured half-life in humans was 5.8 to 8.1 days. Ipamorelin is a five-amino-acid ghrelin mimic, developed by Novo Nordisk and introduced in 1998 as "the first selective growth hormone secretagogue" — pharmacology worked out in rat cells, rats, and swine, not people. Both prod the pituitary to release the body's own growth hormone (GH), usually sold as one combined injection.

A 2026 review in Frontiers in Endocrinology maps the market: both are sold as "research compounds" despite what its authors call the "absence of regulatory approval for physique- or performance-related indications," and a 2026 Sports Medicine review classes both among unapproved peptides for which "rigorous human safety data are scarce, and there is potential for serious harm." Here is what has been measured in humans.

The human evidence, study by study

CJC-1295: two small trials in healthy adults, twenty years ago

The core evidence is a 2006 paper by Teichman and colleagues: two randomized, double-blind, placebo-controlled ascending-dose studies in healthy adults aged 21 to 61, lasting 28 and 49 days. A single injection raised mean GH 2- to 10-fold for six days or more and IGF-1 1.5- to 3-fold for 9 to 11 days; after repeated doses, IGF-1 stayed above baseline for up to 28 days. The authors reported no serious adverse reactions — in studies built to measure hormone levels, not health outcomes. A companion study in healthy men aged 20 to 40 and a 2009 proteomic analysis of 11 healthy young men complete the published human record. No study measured body composition, strength, sleep, injury recovery, or aging — in anyone.

The one attempt to test it in patients: developer ConjuChem registered a phase 2 trial in HIV patients with visceral obesity in 2005, and ClinicalTrials.gov lists it as terminated, with no results and no reason posted — the only CJC-1295 trial in the registry.

Ipamorelin: a pharmacology study, then a failed trial

Ipamorelin's human record begins with a 1999 pharmacokinetic study of escalating 15-minute infusions in healthy male volunteers, eight per dose level: a single pulse of GH, then a decline "to negligible GH concentration at all doses," with a half-life of about two hours. Its one published randomized trial in patients, fifteen years later, was not for anything a wellness clinic sells: a phase 2, double-blind study of intravenous ipamorelin to speed bowel recovery after abdominal surgery. Among 114 analyzed patients, median time to first tolerated meal was 25.3 hours on ipamorelin versus 32.6 on placebo — p = 0.15; in the authors' words, "no significant differences between ipamorelin and placebo in the key and secondary efficacy analyses." A second phase 2 trial enrolled 320 patients and completed in May 2014; no results were ever posted, and no trial of ipamorelin as a study drug has been registered since. (The registry's one later entry to mention it, a 2026 observational study of combat veterans, lists ipamorelin only among the components of a multi-ingredient supplementation program — not as a tested intervention.)

What has never been studied

PubMed indexes exactly two clinical trials for CJC-1295 and two for ipamorelin — the studies above. There is no published randomized trial of either, in any population, for anti-aging, body composition, muscle gain, fat loss, sleep, or recovery. The combination itself — the product clinics actually inject — has never been the subject of any published human study: a PubMed search for both names together returns only reviews and anti-doping laboratory papers. The 2026 Frontiers review reaches the same conclusion, grading these peptides on tiers running down to "a complete absence of human studies," with "uncertainty around putative performance and recomposition benefits."

Raising GH is not a health outcome

The healthy-volunteer data show these molecules do what their pharmacology predicts: GH and IGF-1 go up. The gap is between that lab value and a benefit you can feel — the cleanest illustration is tesamorelin, from the same GHRH family. Sold as Egrifta, it has been FDA-approved since 2010 for exactly one thing: "the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy." Its label warns that it is "not indicated for weight loss management as it has a weight neutral effect." The one family member that ran full trials earned a single narrow indication — and even it is not a weight-loss or anti-aging drug.

Peptides span the spectrum from rigorously proven to never tested — GLP-1 drugs are peptides too, at the proven end. When a clinic says "peptides work," ask which peptide, for what, shown how.

The legal status, precisely

Neither is an FDA-approved drug, so the only lawful route to a prescription product is compounding. Under section 503A, a compounded drug's bulk ingredient must have a USP/NF monograph, be a component of an approved drug, or appear on FDA's 503A bulks list; per FDA's January 2025 interim policy guidance, a product compounded from a substance meeting none of the three "is not eligible for the exemptions in section 503A and may violate the FD&C Act." While nominations are evaluated, FDA sorts substances into categories — under parallel interim policies for 503A pharmacies and 503B outsourcing facilities; Category 2 holds those for which "FDA has identified significant safety risks relating to the use of these substances in compounding."

Per FDA's category page, updated April 22, 2026: ipamorelin acetate appears in Category 2, dated September 29, 2023, under the 503B (outsourcing-facility) policy. CJC-1295 now appears on the page's list of substances "previously in category 2" whose nominations were withdrawn — a list that also names BPC-157, and even ipamorelin acetate, whose entry carries the page's own note that it "also appears in the table above because it is in category 2 under the 503B interim policy": withdrawing a nomination under one track leaves the Category 2 listing under the other standing. Withdrawal is not vindication: FDA's guidance states that a withdrawal "do[es] not reflect a determination by FDA regarding the validity of the nomination," and a withdrawn substance is off the path to the bulks list, not on it. Nor did July 2026 change anything: the seven peptides FDA's Pharmacy Compounding Advisory Committee reviewed on July 23–24, 2026 did not include CJC-1295 or ipamorelin; our BPC-157 report covers that meeting and why even a winning vote changes nothing by itself.

In the gray market, vials carry a "research use only" disclaimer. FDA has said what that is worth: in a March 2026 warning letter to a peptide vendor, it wrote that despite "Research Use Only" labeling, "evidence obtained from your website establishes that your products are intended to be drugs for human use." The label protects the storefront, not the buyer.

Why clinics offer them anyway

Growth hormone itself is singled out by federal statute. Under 21 U.S.C. § 333(e), knowingly distributing human growth hormone "for any use in humans other than the treatment of a disease or other recognized medical condition" authorized by the Secretary and ordered by a physician is a federal crime carrying up to five years in prison — the statute defines HGH as "somatrem, somatropin, or an analogue of either of them." No statute names secretagogues, and that gap is the sales pitch: products that make your pituitary release its own GH, marketed — per the Frontiers review — through "online self-administration protocols" for goals no regulator has approved. The same review catalogs reported adverse effects across GH-axis peptides — cortisol and prolactin elevations, blood-sugar disturbances, fluid retention, joint and muscle aches, injection-site reactions — plus "biologically plausible but unproven mitogenic concerns": the worry that years of elevated IGF-1 could feed tumor growth, unstudied because no one has run the trials.

Questions to ask a clinic that offers CJC-1295/ipamorelin

• Is either substance an approved drug, anywhere, for anything? (No — the approved relative is tesamorelin.)
• Can you name one randomized trial of this combination for my goal? (We found none, for any goal.)
• Ipamorelin acetate is in FDA's Category 2 — "significant safety risks". How do you square that with prescribing it?
• Who compounds it — a 503A pharmacy, a 503B facility, or a "research chemical" vendor — and may I see the certificate of analysis?
• You propose to raise my GH and IGF-1 for weeks at a time (IGF-1 stayed elevated up to 28 days in the CJC-1295 studies). Who monitors those levels, and what result would make you stop?
• What does this cost per month? (Our peptide-clinic cost review is a starting point.)

None of this says the molecules do nothing; they move hormones. It says that twenty years on, no one has shown that moving those hormones makes anyone leaner, stronger, younger, or better rested. The companies that owned these compounds walked away rather than find out.